Intuitive Surgical stock (US46120E6023): Institutional stake cuts signal valuation debate

Koshinski Asset Management slashed its Intuitive Surgical position by 93.4% in Q4 2025, retaining shares worth $331,000, amid mixed institutional moves and a stock opening at $450.06.

Intuitive Surgical, Inc. saw significant institutional activity in the fourth quarter of 2025, with Koshinski Asset Management reducing its stake by 93.4%, selling 8,278 shares and holding 584 shares valued at approximately $331,000, MarketBeat as of 05/11/2026. Meanwhile, Turning Point Benefit Group increased its position by 833.3%, highlighting divergent investor views on the robotic surgery leader. The stock opened at $450.06 on Nasdaq on May 11, 2026.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Intuitive Surgical, Inc.
• Sector/industry: Medical devices, robotic-assisted surgery
• Headquarters/country: United States
• Core markets: Global hospitals and surgical centers
• Key revenue drivers: da Vinci systems, instruments, services
• Home exchange/listing venue: Nasdaq (ISRG)
• Trading currency: USD

Intuitive Surgical: core business model

Intuitive Surgical dominates the minimally invasive robotic surgery market with its da Vinci surgical systems, which enable precise procedures through surgeon-controlled robotic arms. The company generates recurring revenue from instruments, accessories, and services tied to system usage. This model supports stable cash flows as installed base grows globally, including key US hospital networks.

Main revenue and product drivers for Intuitive Surgical

Primary revenue comes from da Vinci system placements, with significant contributions from recurring items like single-use instruments and maintenance services, which accounted for the majority of sales in recent periods. Quarterly revenue reached $2.77 billion, up 23.0% year-over-year as reported for the latest period, exceeding estimates of $2.62 billion, MarketBeat earnings page as of 05/11/2026. US procedures drive substantial growth amid rising adoption in general surgery and other specialties.

Industry trends and competitive position

The robotic surgery sector benefits from AI integration and demand for less invasive procedures, positioning Intuitive Surgical as the market leader with over 90% share in the US. Competitors like Medtronic trail in system deployments, while Intuitive's installed base fuels procedure growth. The stock traded at $450.06 USD on 05/11/2026 on Nasdaq, MarketBeat as of 05/11/2026, down 19.3% year-to-date per recent analysis.

Why Intuitive Surgical matters for US investors

As a Nasdaq-listed leader in medtech, Intuitive Surgical offers US investors exposure to healthcare innovation, with strong ties to the domestic hospital sector representing a core growth driver. Its $10.58 billion annual revenue underscores scale in a market projected to expand with aging demographics and tech adoption.

Conclusion

Recent institutional shifts, including Koshinski's sharp cut and others' increases, reflect debate over Intuitive Surgical's valuation amid a year-to-date pullback. With robust revenue growth and US market dominance, the company remains central to robotic surgery trends. Investors track procedure volumes and earnings for insights into sustained leadership.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.